Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 11/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20252235 | 0.90 | HRH4 (0.36) | PRCPHRH4PRMT5WDR77MEN1 | |
| SCHEMBL17303562 | 0.85 | HRH4 (0.39) | PRCPTLR9TLR8TLR7HRH4 | |
| SCHEMBL19171103 | 0.83 | HRH4 (0.41) | PRCPTLR9TLR8TLR7HRH4 | |
| SCHEMBL19633720 | 0.82 | GPR119 (0.46) | PRCPGPR119 | |
| SCHEMBL25059342 | 0.82 | HRH4 (0.37) | PRCPTLR9TLR8TLR7HRH4 | |
| SCHEMBL19171628 | 0.82 | HRH4 (0.42) | PRCPHRH4PRMT5WDR77MEN1 | |
| SCHEMBL18672902 | 0.81 | HRH4 (0.38) | HRH4PRMT5WDR77MEN1KMT2A | |
| SCHEMBL18672929 | 0.80 | HRH4 (0.47) | HRH4PRMT5WDR77MEN1KMT2A | |
| SCHEMBL15833968 | 0.80 | HRH4 (0.37) | HRH4PRMT5WDR77MEN1KMT2A | |
| SCHEMBL18673096 | 0.78 | PRMT5 (0.39) | PRCPTLR9TLR8TLR7PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | PRCP 2399/4885TLR9 4453/4885TLR8 4804/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | PRCP 2399/4885TLR9 4453/4885TLR8 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.